Welcome to our dedicated page for Merck & Co. news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co. stock.
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a renowned American multinational pharmaceutical company headquartered in Rahway, New Jersey. Originally the American arm of Germany's Merck Group founded in 1668, Merck has established itself as a global leader in pharmaceuticals and vaccines.
Merck's core business is the development and manufacturing of medications and vaccines spanning several therapeutic areas such as cardiometabolic diseases, cancer, and infections. The company's immuno-oncology platform, particularly strong in cancer treatment, is a significant revenue driver. The firm’s oncology portfolio includes groundbreaking immunotherapies like KEYTRUDA, designed to treat melanoma and other cancers. KEYTRUDA, in combination with other therapies, has shown promising results in reducing cancer recurrence and improving survival rates.
Merck also boasts a robust vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their commitment to public health extends to Merck for Mothers, an initiative aimed at improving maternal health globally. In 2024, Merck surpassed its goal early by reaching over 30 million women with programs promoting safe, high-quality maternal care.
The company's animal health division is another sector of its diverse operations, providing solutions to improve animal health and productivity.
From a geographical perspective, nearly half of Merck's sales are generated in the United States. Financially, Merck maintains a solid position with ongoing investments in research and development to fuel innovation. The company is actively engaged in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.
Merck’s mission is rooted in scientific excellence and an unwavering commitment to improving lives. The company continues to invest in leading-edge research, with over 2,250 ongoing clinical trials, including more than 1,600 trials evaluating combination regimens. This dedication underpins Merck's strategy to address complex health challenges and advance global health.
Merck (NYSE: MRK) reported its Q1 2021 financial results, showing total sales of $12.08 billion, a marginal increase from $12.057 billion in Q1 2020. GAAP net income fell by 1% to $3.179 billion, with GAAP EPS at $1.25. Non-GAAP EPS declined 7% to $1.40. Oncology sales were strong, led by KEYTRUDA, which grew 19% to $3.9 billion. However, the pandemic negatively impacted vaccine sales, particularly for GARDASIL, by approximately $230 million. Merck anticipates 2021 revenue growth of 8%-12%, with a GAAP EPS outlook of $5.05-$5.25.
Merck (NYSE: MRK) announced an upcoming virtual investor event on May 3 at 10:00 am EDT, where Organon management will unveil the business strategy and financial outlook for the spinoff company focused on women's healthcare. With over 60 established medicines, Organon aims to leverage a robust cash flow and commercial capabilities to foster growth and partnerships in international markets. Interested participants can pre-register for the event and access additional resources online.
Merck (NYSE: MRK) has entered into non-exclusive licensing agreements for molnupiravir with five Indian generics manufacturers to enhance its availability in India and over 100 low- and middle-income countries. This investigational oral antiviral agent is currently in a Phase 3 trial for non-hospitalized COVID-19 patients. The generics include Cipla, Dr. Reddy’s, Emcure, Hetero, and Sun Pharma. Additionally, Merck will donate over $5 million in aid to support relief efforts in India, highlighting its commitment to alleviating suffering amid the pandemic.
Merck (NYSE: MRK) aims to achieve carbon neutrality across its operations by 2025 and cut 30% of value chain emissions by 2030. These goals align with global climate efforts and the Paris Agreement. Merck plans to enhance efficiency, reduce fossil fuel use, and offset remaining emissions with high-quality carbon credits.
The company has signed new virtual power purchase agreements in Texas and Spain, aiming to address 35% of its Scope 2 emissions. Merck is committed to sustainability and engaging suppliers to achieve these ambitious environmental goals.
Merck (NYSE: MRK) has announced the discontinuation of MK-7110's development for COVID-19 treatment. Acquired through OncoImmune in December 2020, the drug required more data than previously expected, which would delay its availability until 2022. Consequently, Merck will redirect resources towards enhancing molnupiravir, an oral outpatient medicine, and increasing production of Johnson & Johnson's COVID-19 vaccine. This decision aligns with Merck's commitment to prioritize impactful efforts during the pandemic, as stated by Dr. Roy Baynes, senior vice president at Merck Research Laboratories.
Merck (NYSE: MRK) and Ridgeback Biotherapeutics announced updates on molnupiravir, an investigational COVID-19 antiviral. Following positive interim data from the Phase 2 dose-finding trials, Merck will advance molnupiravir to the Phase 3 stage in outpatients with COVID-19, focusing on an 800 mg dosage. However, the drug's Phase 2 MOVe-IN trial for hospitalized patients was halted due to insufficient evidence of clinical benefit. Final data from the MOVe-OUT Phase 3 trial is expected by September/October 2021, with potential Emergency Use Authorization anticipated later in the year.
Merck (NYSE: MRK) announced its 20th community-based grant under the Safer Childbirth Cities initiative, focusing on improving maternal health outcomes for Black women in Austin, TX. The funding supports the Maternal Health Equity Collaborative (MHEC) to address racial inequities and enhance access to quality healthcare. The initiative aligns with Black Maternal Health Week (April 11-17, 2021), spotlighting systemic racism's impact on maternal mortality rates. Merck for Mothers pledges $500 million to combat these disparities, emphasizing local solutions.
Organon Finance 1 LLC, a Merck subsidiary, has priced an offering of €1.25 billion in euro senior secured notes and $4.1 billion in U.S. dollar senior secured notes, alongside $2 billion in senior unsecured notes. This move supports the spinoff of Organon & Co. and aims to repay intercompany loans and cover spinoff-related expenses. The notes will close on April 22, 2021, and will be guaranteed by Organon’s subsidiaries post-spinoff. The offering will cater to qualified institutional buyers and non-U.S. investors, complying with U.S. and EU regulations.
Merck (NYSE: MRK) announced that its Phase 3 KEYNOTE-564 trial for KEYTRUDA, an anti-PD-1 therapy, has met its primary endpoint of disease-free survival (DFS) in patients with renal cell carcinoma (RCC) following nephrectomy. An interim analysis showed a statistically significant improvement in DFS compared to placebo. The trial will continue to assess overall survival, a key secondary endpoint. The safety profile of KEYTRUDA remained consistent with previous studies. Results will be presented at a medical meeting and submitted for regulatory review.
Merck (NYSE: MRK) announced that Organon Finance 1 LLC plans to offer euro-denominated senior secured notes due 2028 and U.S. dollar-denominated senior secured and unsecured notes due 2028 and 2031, respectively. The proceeds will be used to repay intercompany loans and cover spinoff expenses from Merck to Organon & Co. Notes offerings will be subject to market conditions and held in escrow until spinoff conditions are met. The spinoff will form Organon, focusing on women's healthcare with a portfolio of over 60 medicines, strong cash flows, and around 10,000 employees.
FAQ
What is the current stock price of Merck & Co. (MRK)?
What is the market cap of Merck & Co. (MRK)?
What are the main therapeutic areas Merck focuses on?
What is Merck for Mothers?
What are some of Merck’s key products in oncology?
How significant is Merck’s vaccine business?
Where is Merck headquartered?
What percentage of Merck’s sales comes from the United States?
What is Merck's approach to research and development?
What recent achievements has Merck announced?
Does Merck collaborate with other companies for research?
What is the historical origin of Merck & Co., Inc.?
